WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H124844
CAS#: N/A
Description: Mitaplatin is a PDK inhibitor.
Hodoodo Cat#: H124844
Name: Mitaplatin
CAS#: N/A
Chemical Formula: C4H8Cl6N2O4Pt
Exact Mass: 552.83
Molecular Weight: 555.900
Elemental Analysis: C, 8.64; H, 1.45; Cl, 38.26; N, 5.04; O, 11.51; Pt, 35.09
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: Mitaplatin; Mita-platin; Mita platin
IUPAC/Chemical Name: N/A
InChi Key: SFQVINCQRGGSPW-UHFFFAOYSA-J
InChi Code: InChI=1S/2C2H2Cl2O2.2ClH.2H3N.Pt/c2*3-1(4)2(5)6;;;;;/h2*1H,(H,5,6);2*1H;2*1H3;/q;;;;;;+4/p-4
SMILES Code: O=C(C(Cl)Cl)O[Pt](Cl)([NH3])(Cl)([NH3])OC(C(Cl)Cl)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 555.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1: Dhar S, Lippard SJ. Mitaplatin, a potent fusion of cisplatin and the orphan
drug dichloroacetate. Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22199-204.
doi: 10.1073/pnas.0912276106. Epub 2009 Dec 10. PMID: 20007777; PMCID:
PMC2799774.
2: Xue X, You S, Zhang Q, Wu Y, Zou GZ, Wang PC, Zhao YL, Xu Y, Jia L, Zhang X,
Liang XJ. Mitaplatin increases sensitivity of tumor cells to cisplatin by
inducing mitochondrial dysfunction. Mol Pharm. 2012 Mar 5;9(3):634-44. doi:
10.1021/mp200571k. Epub 2012 Feb 13. PMID: 22289032; PMCID: PMC3310394.
3: Johnstone TC, Kulak N, Pridgen EM, Farokhzad OC, Langer R, Lippard SJ.
Nanoparticle encapsulation of mitaplatin and the effect thereof on in vivo
properties. ACS Nano. 2013 Jul 23;7(7):5675-83. doi: 10.1021/nn401905g. Epub
2013 May 22. PMID: 23697579; PMCID: PMC3722263.